(Alliance News) - Inspiration Healthcare Group PLC on Friday said it has agreed to distribute Genedrive PLC's antibiotic induced hearing loss test in the UK and Ireland.
The Genedrive MT-RNR1 is a genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics.
It is expected that the scope of the contract between Genedrive and Inspiration Healthcare will be expanded over time to engage Inspiration Healthcare's network of over 50 neonatal focussed sub-distributors around the world.
"Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with Genedrive to make this test the standard of care in the UK and the wider neonatal community around the world," said Inspiration Healthcare Chief Executive Neil Campbell.
"Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together," added Genedrive CEO David Budd.
Inspiration Healthcare shares were trading 4.5% higher in London on Friday at 64.78 pence each, while Genedrive shares were up 13% at 81.95p each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Inspiration Hlt (IHC)
Genedrive (GDR)